Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study

BACKGROUND: Optimal treatment for secondary hyperparathyroidism (SHPT) has not been defined. The IMPACT SHPT (ClinicalTrials.gov identifier: NCT00977080) study assessed whether dose-titrated paricalcitol plus supplemental cinacalcet only for hypercalcaemia is superior to cinacalcet plus low-dose vit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ketteler, Markus, Martin, Kevin J., Wolf, Myles, Amdahl, Michael, Cozzolino, Mario, Goldsmith, David, Sharma, Amit, Marx, Steven, Khan, Samina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408938/
https://www.ncbi.nlm.nih.gov/pubmed/22387567
http://dx.doi.org/10.1093/ndt/gfs018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408938/
https://www.ncbi.nlm.nih.gov/pubmed/22387567
http://dx.doi.org/10.1093/ndt/gfs018

Ejemplares similares